$208 Million is the total value of Aisling Capital Management LP's 16 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $100,609,513 | +117.6% | 6,068,125 | 0.0% | 48.41% | +58.6% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $24,769,455 | +267.9% | 798,757 | 0.0% | 11.92% | +168.1% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $21,648,000 | -17.0% | 1,025,000 | 0.0% | 10.42% | -39.5% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $11,469,458 | +2.4% | 1,472,331 | 0.0% | 5.52% | -25.4% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $5,386,329 | +100.0% | 2,834,910 | 0.0% | 2.59% | +45.8% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $5,298,729 | +156.7% | 886,075 | 0.0% | 2.55% | +87.1% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $4,218,075 | -13.5% | 2,541,009 | 0.0% | 2.03% | -37.0% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $3,514,741 | -48.6% | 434,455 | 0.0% | 1.69% | -62.6% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $3,213,262 | -41.9% | 1,043,267 | 0.0% | 1.55% | -57.6% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $2,664,179 | +101.5% | 1,205,511 | 0.0% | 1.28% | +46.8% | |
| AVRO | AVROBIO, Inc. (AVRO) | $1,009,779 | +40.8% | 1,009,779 | 0.0% | 0.49% | +2.7% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $490,434 | -35.6% | 1,691,151 | 0.0% | 0.24% | -53.0% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $458,828 | +8.9% | 288,571 | 0.0% | 0.22% | -20.5% | |
| BCEL | Atreca Inc. (BCEL) | $441,924 | +42.3% | 387,653 | 0.0% | 0.21% | +3.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.